Business Context and Reporting Period
The filing is Histogenics Corporation’s unaudited Form 10-Q for the three months ended March 31, 2016. The request metadata identifies Ocugen, Inc., but the supplied filing is for Histogenics Corporation; investors should verify the issuer identity.
Histogenics was a clinical-stage regenerative medicine company developing musculoskeletal products, principally NeoCart, a cartilage-repair product in a U.S. Phase 3 clinical trial under an FDA special protocol assessment. The company had not generated revenue from its planned principal operations and had not obtained regulatory approval for a product.
Financial Highlights
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $5.586 million | $5.764 million | Down $0.178 million, 3% |
| General and administrative expense | $2.212 million | $2.109 million | Up $0.103 million, 5% |
| Total operating expenses | $7.798 million | $7.873 million | Down $0.075 million, 1% |
| Net loss | $7.918 million | $7.964 million | Improved by $0.046 million |
| Net loss per share | $0.60 | $0.60 | No change |
| Cash used in operating activities | $7.841 million | $8.689 million | Improved by $0.848 million |
| Cash and cash equivalents, March 31 | $22.897 million | $53.181 million | Down $30.284 million |
There was no meaningful operating margin because the company had no revenue and incurred operating losses. The accumulated deficit was $173.483 million at March 31, 2016, compared with $165.565 million at December 31, 2015.
Total assets were $28.515 million and total liabilities were $7.923 million at March 31, 2016. Equipment loan debt totaled $1.198 million, including $583,000 classified as current. The company was in compliance with its debt covenants. No off-balance-sheet arrangements were reported.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined primarily because the prior-year period included $413,000 of raw-material purchases and $105,000 more consulting expense. These savings were partly offset by $140,000 of higher salary costs and $216,000 of higher clinical-trial costs.
- General and administrative expense increased primarily because of approximately $75,000 in recruiting fees and approximately $60,000 of additional stock-based compensation, partly offset by lower directors’ and officers’ insurance expense.
- Operating cash burn improved 10%, while investing cash use declined from $915,000 to $32,000 because of lower property and equipment purchases.
- Financing activity changed from $4.725 million of net proceeds in Q1 2015, largely from the IPO overallotment, to $145,000 of net cash used in Q1 2016, primarily debt repayment.
- Cash declined by $8.018 million during Q1 2016, compared with a $4.879 million decline in Q1 2015.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing cash and cash equivalents to fund projected needs into 2017, but stated that additional capital would be required to complete NeoCart trial enrollment and further develop product candidates.
- The filing states that enrollment guidance for the NeoCart Phase 3 trial had previously been moved from June 2016 to June 2017 because enrollment trends were below expectations.
- Management expected continued net losses and significant expenses for at least the next several years, with no significant product revenue anticipated unless NeoCart or another product candidate receives regulatory approval and is commercialized.
- The company was transitioning manufacturing of key NeoCart raw materials to in-house facilities and third-party sources. FDA comparability determinations, facility approvals, manufacturing yields, quality control and supply availability could delay clinical development or commercialization.
- In April 2016, the FDA approved the company’s submission supporting equivalence data for collagen manufactured at its Westview, Massachusetts facility; the filing stated that no additional patient equivalence studies would be required for that collagen.
- On May 10, 2016, after quarter-end, the company acquired development and commercialization rights to NeoCart in Japan from Purpose. Consideration includes success-based and commercial milestones and a low single-digit royalty on Japanese sales if approved.
- Other commitments included a potential $190,000 payment upon acceptance of a multi-unit bioreactor system, a remaining $30,000 payment under a collagen supply agreement, license milestones and royalties, and operating lease obligations.
- Key risks included failure or delay of clinical trials, patient-enrollment shortfalls, FDA approval and manufacturing-comparability requirements, need for additional financing, dilution or restrictive debt terms, competition, intellectual-property disputes, reliance on third parties and key personnel, and limited manufacturing capacity.
Investor Verification Priorities
- Verify that the filing issuer is Histogenics Corporation rather than Ocugen, Inc., and confirm whether the requested company-period pairing is correct.
- Confirm current cash runway, subsequent financing, and whether management’s expectation of funding into 2017 was achieved.
- Track NeoCart Phase 3 enrollment, trial completion timing, clinical results and any FDA requirements or holds.
- Verify FDA acceptance of manufacturing comparability and approval status of the Waltham and Lexington facilities and multi-unit reactor.
- Review subsequent events, including the Japan NeoCart rights transaction and any related milestone or royalty obligations.
- Assess future dilution and financing risk given the $173.5 million accumulated deficit, continuing losses and stated need for additional capital.